Venous thromboembolism in multiple myeloma: Current perspectives in pathogenesis

European Journal of Cancer

Volumn 46, Issue 10, 2010, Pages 1790-1799

  Uaprasert, Noppacharn ^a,b   Voorhees, Peter M ^a   Mackman, Nigel ^a   Key, Nigel S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Multiple myeloma; Pathogenesis; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ANTIANEMIC AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BORTEZOMIB; C REACTIVE PROTEIN; CHECKPOINT KINASE 1; DEXAMETHASONE; DOXORUBICIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPIRUBICIN; FIBRINOGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LENALIDOMIDE; MELPHALAN; PHOSPHATIDYLSERINE; PREDNISONE; PROTEIN C; RISTOCETIN; THALIDOMIDE; THROMBIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VINCRISTINE; VON WILLEBRAND FACTOR; ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 5;

ANTICOAGULATION; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; COMORBIDITY; CYTOKINE PRODUCTION; DNA REPAIR; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENDOTHELIUM CELL; FIBRINOLYSIS; GENE MUTATION; HEREDITY; HUMAN; IN VITRO STUDY; INCIDENCE; MULTIPLE MYELOMA; PARACRINE SIGNALING; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; COMPLICATION; GENETICS; MUTATION; PHYSIOLOGY; RISK FACTOR;

ANTINEOPLASTIC AGENTS; FACTOR V; FIBRINOLYSIS; HUMANS; MULTIPLE MYELOMA; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 77953478259     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.03.007     Document Type: Article

References (122)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 59 (2009) 225-249
3. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111 (2008) 2516-2520
4. El Accaoui R.N., Shamseddeen W.A., and Taher A.T. Thalidomide and thrombosis. A metaanalysis. Thromb Haemost 97 (2007) 1031-1036
5. Bennett C.L., Angelotta C., Yarnold P.R., et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 296 (2006) 2558-2560
6. Zangari M., Tricot G., Polavarum L., et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol 28 (2009) 132-135
7. Blom J.W., Doggen C.J., Osanto S., and Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293 (2005) 715-722
8. Kristinsson S.Y., Fears T.R., Gridley G., et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 112 (2008) 3582-3586
9. Sallah S., Husain A., Wan J., Vos P., and Nguyen N.P. The risk of venous thromboembolic disease in patients with monoclonal gammopathy with undetermined significance. Ann Oncol 15 (2004) 1490-1494
10. Srkalovic G., Cameron M.G., Rybicki L., Deitcher S.R., Kattke-Marchant K., and Hussein M.A. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venous thromboembolic disease. Cancer 101 (2004) 558-566
11. Kyle R.A., and Rajkumar S.V. Multiple myeloma. Blood 111 (2008) 2962-2972
12. Osman K., Comenzo R., and Rajkumar S.V. Deep venous thrombosis and thalidomide therapy for multiple myeloma. New Engl J Med 344 (2001) 1951-1952
13. Cavo M., Zamagni E., Tosi P., et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106 (2005) 35-39
14. Palumbo A., Bringhen S., Caravita T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 (2006) 825-831
15. Zonder J.A., Barlogie B., Durie B.G., McCoy J., Crowley J., and Hussein M.A. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 108 (2006) 403
16. Facon T., Mary J.Y., Pegourie B., et al. Dexamethasone based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 107 (2006) 1292-1298
17. Facon T., Mary J.Y., Hulin C., et al. Melphalan and prednisone plus thalidomide versus melphalan prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370 (2007) 1209-1218
18. San Miguel J.E., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New Engl J Med 359 (2008) 906-917
19. Rifkin R.M., Gregory S.A., Mohrbacher A., and Hussein M.A. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer 106 (2006) 848-858
20. Jimenez-Zepeda V.H., and Dominguez-Martinez V.J. Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?. Eur J Haematol 77 (2006) 239-244
21. Rajkumar S.V., Blood E., Vesole D., Fonseca R., and Greipp P.R. Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24 (2006) 431-436
22. Rajkumar S.V., Rosiñol L., Hussein M., et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 26 (2008) 2171-2177
23. Lonial S., Richarson P.G., San Miguel J., et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Brit J Haematol 143 (2008) 222-229
24. Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapse or refractory multiple myeloma. New Engl J Med 357 (2007) 2123-2132
25. Weber D.M., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New Engl J Med 357 (2007) 2133-2142
26. Weber D., Rankin K., Gavino M., Delasalle K., and Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21 (2003) 16-19
27. Rajkumar S.V., Gertz M.A., Lacy M.Q., et al. Thalidomide as initial therapy for early-phase myeloma. Leukemia 17 (2003) 775-779
28. Barlogie B., Desikan R., Eddlemon P., et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98 (2001) 492-494
29. Mileshkin L., Biagi J.J., Mitchell P., et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 102 (2003) 69-77
30. Prince H.M., Mileshkin L., Roberts A., et al. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. Clin Cancer Res 11 (2005) 5504-5514
31. Rajkumar S.V., Hayman S., Gertz M.A., et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20 (2002) 4319-4323
32. Anagnostopoulos A., Weber D., Rankin K., Delasalle K., and Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Brit J Haematol 121 (2003) 768-771
33. Palumbo A., Bertola A., Falco P., et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 5 (2004) 318-324
34. Zervas K., Dimopoulos M.A., Hatzicharissi E., et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 15 (2004) 134-138
35. Baz R., Li L., Kottke-Marchant K., et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline based chemotherapy for multiple myeloma. Mayo Clin Proc 80 (2005) 1568-1574
36. Schütt P., Ebeling P., Buttkereit U., et al. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur J Haematol 74 (2005) 40-46
37. Hussein M.A., Baz R., Srkalovic G., et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 81 (2006) 889-895
38. Richardson P.G., Blood E., Mitsiades C.S., et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or refractory multiple myeloma. Blood 108 (2006) 3458-3464
39. Richardson P., Jagannath S., Hussein M., et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 114 (2009) 772-778
40. Rajkumar S.V., Jacobus S., Callander N.S., et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11 (2010) 29-37
41. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New Engl J Med 352 (2005) 2487-2498
42. Harousseau J.L., Attal M., Leleu X., et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 91 (2006) 1498-1505
43. Rosinol L., Oriol A., Mateos M.V., et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 25 (2007) 4452-4458
44. Orlowski R.Z., Nagler A., Sonneveld P., et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25 (2007) 3892-3901
45. Palumbo A., Gay F., Bringhen S., et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 19 (2008) 1160-1165
46. Jagannath S., Durie B.G., Wolf J.L., et al. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Brit J Haematol 146 (2009) 619-626
47. Palumbo A., Ambrosini M.T., Benevolo G., et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109 (2007) 2767-2772
48. Terpos E., Kastritis E., Roussou M., et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 22 (2008) 2247-2256
49. Richardson P.G., Jagannath S., Avigan D.E., et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial. Blood 108 (2006) [abstract 405]
50. Popat R., Oakervee H.E., Hallam S., et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Brit J Haematol 141 (2008) 512-516
51. Bennett C.L., Silver S.M., Djulbegovic B., et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299 (2008) 914-924
52. Bohlius J., Schmidlin K., Brillant C., et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373 (2009) 1532-1542
53. Knight R., DeLap R.J., and Zeldis J.B. Lenalidomide and venous thrombosis in multiple myeloma. New Engl J Med 354 (2006) 2079-2080
54. Katodritou E., Verrou E., Hadjiaggelidou C., et al. Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol 83 (2008) 697-701
55. Galli M., Elice F., Crippa C., Comotti B., Rodeghiero F., and Barbui T. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica 89 (2004) 1141-1142
56. Aapro M., Osterwalder B., Scherhag A., and Burger H.U. Epoetin-beta treatment in patients with cancer chemotherapy-induced anemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumor progression and thromboembolic events. Brit J Cancer 101 (2009) 1961-1971
57. Rizzo J.D., Somerfield M.R., Hagerty K.L., et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 111 (2008) 25-41
58. Khorana A.A., and Connolly G.C. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 27 (2009) 4839-4847
59. Elice F., Fink L., Tricot G., Barlogie B., and Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Brit J Haematol 134 (2006) 399-405
60. Johnson D.C., Corthals S., Ramos C., et al. Genetic associations with thalidomide mediated venous thromboembolic events in myeloma identified using targeted genotyping. Blood 112 (2008) 4924-4934
61. Petropoulou A.D., Gerotziafas G.T., Samama M.M., Hatmi M., Rendu F., and Elalamy I. In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide. Thromb Res 121 (2008) 493-497
62. van Hylckama Vlieg A., Christiansen S.C., Luddington R., Cannegieter S.C., Rosendaal F.R., and Baglin T.P. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Brit J Haematol 138 (2007) 769-774
63. Hron G., Kollars M., Binder B.R., Eichinger S., and Kyrle P.A. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 296 (2006) 397-402
64. Tripodi A., Legnani C., Chantarangkul V., Cosmi B., Palareti G., and Mannucci P.M. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost 6 (2008) 1327-1333
65. Auwerda J.J., Sonneveld P., de Maat M.P., and Leebeek F.W. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 92 (2007) 279-280
66. Minnema M.C., Fijnheer R., De Groot P.G., and Lokhorst H.M. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 1 (2003) 445-449
67. van Marion A.M., Auwerda J.J., Lisman T., et al. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res 32 (2008) 1078-1084
68. Kasthuri R.S., Taubman M.B., and Mackman N. Role of tissue factor in cancer. J Clin Oncol 27 (2009) 4834-4838
69. Falanga A., Barbui T., and Rickles F.R. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost 34 (2008) 204-210
70. Negaard H.F., Iversen P.O., Ostenstad B., Iversen N., Holme P.A., and Sandset P.M. Hypercoagulability in patients with hematological neoplasia: no apparent initiation by tissue factor. Thromb Haemost 99 (2008) 1040-1048
71. Ma L., Francia G., Viloria-Petit A., et al. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res 65 (2005) 5365-5373
72. Leebeek F., Yuana Y., Osanto S., et al. Microparticleassociated tissue factor activity and venous thrombosis in multiple myeloma. Blood (2008) 112 [abstract 1812]
73. Kerr R., Stirling D., and Ludlam C.A. Interleukin-6 and haemostasis. Brit J Haematol 115 (2001) 3-12
74. Camera M., Giesen P.L., Fallon J., et al. Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells. Arterioscler Thromb Vasc Biol 19 (1999) 531-537
75. Mechtcheriakova D., Schabbauer G., Lucerna M., et al. Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 15 (2001) 230-242
76. Guha M., O'Connell M.A., Pawlinski R., et al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 98 (2001) 1429-1439
77. Li Y.D., Ye B.Q., Zheng S.X., et al. NF-kappaB transcription factor p50 critically regulates tissue factor in deep vein thrombosis. J Biol Chem 284 (2009) 4473-4483
78. Zangari M., Saghafifar F., Anaissie E., et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrin 13 (2002) 187-192
79. Jimenez-Zepeda V.H., and Dominguez-Martinez V.J. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb J 4 (2006) 11
80. Negaard H.F., Iversen P.O., Ostenstad B., Mowinckel M.C., and Sandset P.M. Increased acquired activated protein C resistance in unselected patients with hematological malignancies. J Thromb Haemost 6 (2008) 1482-1487
81. Gruber A., Blasko G., and Sas G. Functional deficiency of protein C and skin necrosis in multiple myeloma. Thromb Res 42 (1986) 579-581
82. Corso A., Lorenzi A., Terulla V., et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 83 (2004) 588-591
83. Zappasodi P., Mangiacavalli S., Terulla V., et al. Thrombomodulin levels are not modified during thalidomide treatment. Eur J Haematol 77 (2006) 453-454
84. Nan B., Lin P., Lumsden A.B., Yao Q., and Chen C. Effects of TNF-alpha and curcumin on the expression of thrombomodulin and endothelial protein C receptor in human endothelial cells. Thromb Res 115 (2005) 417-426
85. Carr Jr. M.E., and Zekert S.L. Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma. Am J Physiol 266 (1994) H1195-H1201
86. Carr Jr. M.E., Dent R.M., and Carr S.L. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J Lab Clin Med 128 (1996) 83-88
87. Weisel J.W., and Litvinov R.I. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem 6 (2008) 161-180
88. Yagci M., Sucak G.T., and Haznedar R. Fibrinolytic activity in multiple myeloma. Am J Hematol 74 (2003) 231-237
89. van Marion A.M., Auwerda J.J., Minnema M.C., et al. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost 94 (2005) 1341-1343
90. Sharma S., and Lichtenstein A. Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors. Blood 112 (2008) 1338-1345
91. Bottles K.D., and Morrissey J.H. Dexamethasone enhances agonist induction of tissue factor on monocytes but not in endothelial cells. Blood Coagul Fibrin 4 (1993) 405-414
92. Reddy K.V., Bhattacharjee G., Schabbauer G., et al. Dexamethasone enhances LPS induction of tissue factor expression in human monocytic cells by increasing tissue factor mRNA stability. J Leukoc Biol 76 (2004) 145-151
93. Kerachian M.A., Cournoyer D., Harvey E.J., et al. Effect of high-dose dexamethasone on endothelial haemostatic gene expression and neutrophil adhesion. J Steroid Biochem Mol Biol 116 (2009) 127-133
94. van Giezen J.J., and Jansen J.W. Correlation of in vitro and in vivo decreased fibirnolytic activity caused by dexamethasone. Ann NY Acad Sci 667 (1992) 199-201
95. van Giezen J.J., Brakkee J.G., Dreteler G.H., Bouma B.N., and Jansen J.W. Dexamethasone affects platelet aggregation and fibrinolytic activity in rats at different doses which is reflected by their effect on arterial thrombosis. Blood Coagul Fibrin 5 (1994) 249-255
96. Minotti G., Menna P., Salvatorelli E., Cairo G., and Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56 (2004) 185-229
97. Swystun L.L., Shin L.Y., Beaudin S., and Liaw P.C. Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and monocytes. J Thromb Haemost 7 (2009) 619-626
98. Woodley-Cook J., Shin L.Y., Swystun L., Caruso S., Beaudin S., and Liaw P.C. Effects of chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway. Mol Cancer Ther 5 (2006) 3303-3311
99. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Apoptotic signaling induced by thalidomide analogs in human multiple myeloma cells: therapeutic implication. Blood 99 (2002) 4525-4530
100. Arkel Y.S., Ku D.H., and Thurston A.L. The effect of thalidomide on tissue factor activity in Mono Mac 6 cells and the relationship to tumor necrosis factor (TNF)-alpha-stimulated cells. J Thromb Haemost 1 (2003) 2691-2692
101. Cavo M. Proteasome inhibitor bortezomib for treatment of multiple myeloma. Leukemia 20 (2006) 1341-1352
102. Avcu F., Ural A.U., Cetin T., and Nevrus O. Effects of bortezomib on platelet aggregation and ATP release in human platelet, in vitro. Thromb Res 121 (2008) 567-571
103. Zangari M., Guerrero J., Cavallo F., Prasad H.K., Essentine D., and Fink L. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Haematologica 93 (2008) 953-954
104. Hiroi T., Deming C.B., Zhao H., et al. Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Krüppel-like transcription factors. Arterioscler Thromb Vasc Biol 29 (2009) 1587-1593
105. Atkins G.B., and Jain M.K. Role of Krüppel-like transcription factors in endothelial biology. Circ Res 100 (2007) 1686-1695
106. Lin Z., Kumar A., SenBanerjee S., et al. Krüppellike factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res 96 (2005) e48-e57
107. Hamik A., Lin Z., Kumar A., et al. Krüppel-like factor 4 regulates endothelial inflammation. J Biol Chem 282 (2007) 13769-13779
108. Chen Z.Y., Wang X., Zhou Y., Offner G., and Tseng C.C. Destabilization of Krüppel-like factor 4 protein in response to serum stimulation involves the ubiquitin-proteasome pathway. Cancer Res 65 (2005) 10394-10400
109. Hideshima T., Ikeda H., Chauhan D., et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 114 (2009) 1046-1052
110. Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61 (2001) 3071-3076
111. McConkey D.J. Bortezomib paradigm shift in myeloma. Blood 114 (2009) 931-932
112. Zangari M., Barlogie B., Anaissie E., et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Brit J Haematol 126 (2004) 715-721
113. Barlogie B., Tricot G., Anaissie E., et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. New Engl J Med 354 (2006) 1021-1030
114. Klein U., Kosely F., Hillengass J., et al. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol 88 (2009) 67-71
115. Knop S., Gerecke C., Liebisch P., et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 113 (2009) 4137-4143
116. Geerts W.H., Bergqvist D., Pineo G.F., et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (2008) 381S-453S
117. Rajkumar S.V., Hayman S.R., Lacy M.Q., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106 (2005) 4050-4053
118. Palumbo A., Falco P., Corradini P., et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA - Italian Multiple Myeloma Network. J Clin Oncol 25 (2007) 4459-4465
119. Wang M., Weber D.M., Delasalle K., and Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 79 (2005) 194-197
120. Palumbo A., Rajkumar S.V., Dimopoulos M.A., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in multiple myeloma. Leukemia 22 (2008) 414-423
121. Musallam K.M., Dahdaleh F.S., Shamseddine A.I., and Taher A.T. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb Res 123 (2009) 679-686
122. Falanga A., and Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol 27 (2009) 4848-4857